RESEARCH
UPDATE: Emerging Treatments in Fight Against COVID-19 .
COVID-19 research continues to expand rapidly, with hundreds of new interventional trials and many fresh treatment combinations entering the pipeline. Convalescent plasma has gained momentum, while interest in antivirals like lopinavir–ritonavir and remdesivir has cooled somewhat, and favipiravir has seen a noticeable rise. Meanwhile, long-standing favourites—hydroxychloroquine, stem cells, and tocilizumab—remain common across registries. A handful of RCTs have begun to report results, prompting cautious updates from major health agencies, yet most treatments still lack convincing evidence. Across guidelines, the message remains clear: outside research settings, routine use of these therapies is not supported, and high-quality trials are still urgently needed.
Already have an account? Log in
Unlock the Full original article
You have access to 4 more FREE articles this month.
Click below to unlock and view this original article
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
